XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.06

+0.3%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tharos who wrote (10597)	7/1/1999 2:09:00 PM
From: aknahow	Read Replies (2) of 17367

No, I believe world wide rights to E-5 reverted to XOMA when Pfizer gave up. Besides I don't think E-5 is worth that much considering the strategy to not attack the final stage of sepsis directly but rather to try to "cure" the problems that might eventually lead to sepsis. BTW Novartis is involved in the fungal area. Of course it would be difficult to say what they are not into.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next